Authors
Latest:
Developing Nonviral Gene Therapy for Hemophilia ABrent Warner, president, gene therapy, Poseida Therapeutics, discussed data on the preclinical P-FVIII-101 presented at ASH 2022.
Latest:
Expanding the Use of CAR T Therapy With shRNAThe chief executive and chief medical officers of Celyad Oncology discussed the company’s future research and plans.
Latest:
Gregory W. Roloff, MD, on Further Investigation With Sequencing and CAR T in B-ALLThe chief hematology/oncology fellow at University of Chicago discussed further research his center is working on with cell therapy in B-cell acute lymphoblastic leukemia.
Latest:
Jonas Wang, PhD, on the Advantages of Cord Blood-Derived Stem Cells in Regenerative MedicineFor World Cord Blood Day, the chairman and president of StemCyte discussed his thoughts on the importance of cord blood stem cells for the healthcare community.
Latest:
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular DiseaseThe director of the Mount Sinai Fuster Heart Hospital discussed how artificial intelligence complements data-driven research.
Latest:
Monitoring and Support for Patients Receiving CAR T-Cell TherapyExperts discuss providing supportive care to patients receiving CAR T-cell therapy.
Latest:
Stefanie Bailey, PhD, on the Role of Interferon-γ in CAR T-Cell TherapyThe research fellow from Harvard Medical School discussed blocking IFNg as a potential approach to reduce toxicities.
Latest:
Novartis' Rapcabtagene Autoleucel Produces Durable Response in Relapsed/Refractory DLBCLRates of complete response to the novel CAR-T varied from 67% to 75% across the 4 dosage levels tested.
Latest:
Heather Lau, MD, MS, on Using Heparan Sulphate as a Biomarker in the Clinical Study of MPSIIIA Gene Therapy UX111The executive director of global clinical development at Ultragenyx Pharmaceutical discussed the statistical findings she presented at the 2024 WORLDSymposium.
Latest:
Tom Van Blarcom, PhD, on Bringing CAR-T Constructs From Oncology to B-Cell Driven Autoimmune DiseaseThe senior vice president and head of research at Kyverna Therapeutics discussed the company’s investigational CAR-T therapies, KYV-101 and KYV-201.
Latest:
DLBCL Second-Line Therapy RecommendationsExperts discussed their recommendations for second-line treatment options for patients with DLBCL.
Latest:
The Challenges of Gene Therapy Approaches in Advanced Muscular DystrophyKevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa, discussed his mouse model research into the pathophysiology of muscular dystrophy and how it relates to gene therapy approaches.
Latest:
Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for SarcomasThe professor of medicine and pediatrics at Washington University in St. Louis discussed future challenges and exciting research in the sarcoma field.
Latest:
Developing Personalized Immunotherapies for Solid TumorsJessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the company’s focus on solid tumors and manufacturing cell therapies.
Latest:
Ahmad Masri, MD, MS, on the Potential of Cell Therapy in Light Chain AmyloidosisFor World Amyloidosis Day, the cardiologist at the Center for Hypertrophic Cardiomyopathy at Oregon Health & Science University discussed how Nexcella’s NXC-201 could help address unmet needs.
Latest:
Developing MCO-010 for Retinal Degenerative DiseasesSamarendra Mohanty, PhD, cofounder and president, Nanoscope Therapeutics, discussed the company’s technological platforms and RESTORE trial data.
Latest:
Collaboration and Expertise Is Crucial for Cell and Gene Therapy Clinical Trial SuccessParexel cell and gene therapy director Izaskun Elorza, MD, shares key factors for industry to consider as this emerging field becomes more prominent.
Latest:
Supporting the Development of Cell and Gene TherapiesThe chief executive officer of FlowMetric discussed the company’s role in supporting the development of novel gene and cell therapies.
Latest:
Leaping the Next Hurdle in CAR T-Cell TherapiesPhil Cyr, Senior Vice President, Precision Value & Health, discussed challenges to tackle with CAR T-cell therapies.
Latest:
mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia GravisMiloš Miljković, MD, the chief medical officer of Cartesian Therapeutics, discussed data presented at ASGCT 2024 from a phase 2a study.
Latest:
Wolfgang Miesbach, MD, PhD, on Future Research with EtranaDezThe professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed future integration of EtranaDez into hemophilia B treatment.
Latest:
Paulina Velasquez, MD, on Finding New Targets for Cell TherapyThe assistant member at St. Jude Children’s Research Hospital discussed the ASH 2022 basic and translational science session she moderated.
Latest:
Improving Practicality of Cell and Gene TherapiesJosh Ludwig, global director, commercial operations, ScaleReady, discussed making cell and gene therapy widely practical and viable for patients with cancer.
Latest:
Scott McClellan, MD, on Current Trends and Future Trajectories in Cell TherapyThe chief medical officer of Orca Bio discussed some trends he was excited about at ASH’s 2023 conference.
Latest:
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare DiseasesThe director of the Manton Center for Orphan Disease Research at Boston Children’s Hospital discussed takeaways from an MDA session on rare diseases.
Latest:
Brian Koffman, MDCM, on Keeping Pace in Chronic Lymphocytic Leukemia ResearchThe cofounder, executive vice president, and chief medical officer, CLL Society, discussed unmet needs that remain for people with CLL and how the society is working to advance research in the field.
Latest:
Alan Trounson, PhD, MSc, on New Frontiers in Allogeneic Cell TherapyThe chief executive officer of Cartherics discussed the company’s development of NK cell, T-cell, and macrophage cell therapies for various solid tumor indications.
Latest:
Lawrence R. Lustig, MD, on Evaluating Gene Therapy for the Treatment of Otoferlin-Related Hearing LossThe chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians discussed the phase 1/2 CHORD clinical trial evaluating DB-OTO.
Latest:
Stella Vnook, PharmD, on Improving Cell Therapy Delivery to Solid Tumors With Core Shell SpherificationThe chief executive officer of Likarda discussed the company’s CSS technology and how it may reduce off-tissue effects.
